In our center, we have recently adopted a new method of implanting DBS electrodes, portable CT (CereTom). We were interested in how this new methodology would affect the cost of DBS electrode implantation, and the utilization of operating room (OR) resources. In this study, we compared the historical costs of electrode implantation at our institution in patients under local anesthesia, utilizing microelectrode recording to locate targets ("Awake DBS"), to a newer method in which DBS electrodes were implanted under general anesthesia, using only image guidance ("Asleep DBS"). This cost analysis was then benchmarked to the University HealthSystem Consortium (UHC) database for 26 "high-volume" UHC Clinical Database principle member hospitals for DBS electrode and internal pulse generator (IPG) implantation procedures.
methods
At Oregon Health & Science University (OHSU), preoperative MRI is performed just prior to inpatient hospitalization. DBS electrodes are implanted during an initial overnight hospital stay (Phase 1), and IPGs are implanted from 4 to 9 days later in an ambulatory surgery center (Phase 2). Inpatient care, coded by International Classification of Diseases, Ninth Revision (ICD-9) procedure code 0293, includes implantation of an intracranial neurostimulator lead. Outpatient care consists of the preoperative imaging and eventual implantation of an IPG. In an effort to capture all costs associated with DBS, all outpatient and inpatient charge data from patients receiving a DBS implant at a single academic health center (OHSU) were collected. Included outpatient charges were any preoperative charges recorded within 30 days prior to the implant and any postoperative charges recorded up to 30 days after the implant. Charges that were unrelated to DBS were excluded, such as charges for emergency department visits. Inpatient charges that were included were those associated with the ICD-9 code 0293 intracranial implant encounter.
Costs were calculated using a cost-to-charge ratio, which was calculated from the ratio of total direct cost to total charge by item type. The cost-to-charge ratio was then applied to each line-item charge to approximate costs for the respective fiscal year. Cost-to-charge ratios from fiscal year 2013 were applied to charges of fiscal year 2014.
Asleep DBS was compared with awake DBS (performed before year 2011). Top cost contributors by revenue category for each method and total cost, length of stay (LOS), and readmissions were compared. Surgical procedures were performed by 1 surgeon (K.J.B.); therefore, provider comparisons are not included.
For benchmarking purposes, OHSU's implantation of intracranial neurostimulator leads were compared with 26 "high-volume" UHC Clinical Database principle member hospitals. Benchmarking analysis was limited to the inpatient procedure associated with DBS: ICD-9 procedure code 0293, "implantation or replacement of intracranial neurostimulator lead." High volume was defined as greater than or equal to 5 procedures per year. Direct cost indices, total cost, volume, and average total cost per discharge between OHSU and UHC institutions were compared. UHC benchmarking data, mean total cost, mean observed di- rect cost, mean expected direct cost, and direct cost index were queried from January 2011 to March 2014. Queries of mean total cost and direct cost index were compared. In these queries, total cost was defined as the sum of direct and indirect costs. Direct costs are costs specifically associated with providing the service or procedure of interest. Indirect costs are those that are related to support services necessary to the procedures and services specified, but not directly related to delivering care. The direct cost index is the observed direct cost over the expected direct cost. Expected direct costs were generated using the UHC 2013 risk adjustment model. Total DBS cost over time was compared with the upper control limit and lower control limit determined by data from the period prior to January 5, 2011, when OHSU still performed awake DBS procedures.
results demographics
Two hundred eleven DBS cases were included in the study period of July 2009 to March 2014. The average patient age was 65 ± 9 years and 39% were women. Overall primary patient diagnosis was Parkinson's disease (61.1%) and "essential and other specified forms of tremor" (36%). The majority of patients (80%) had minor 3M Severity of Illness, and 97.2% were ultimately discharged home or to self-care; 68.2% of patients were covered by Medicare and 31.3% had private insurance coverage (Table 1) .
inpatient and outpatient costs associated with dbs
All revenue categories were sorted by average per patient cost and the percentage of patients who were billed for the revenue category (% utilization). For revenue categories, the amount of variance and mean cost per patient were as expected based on OHSU clinical practice. However, more utilization was expected in certain categories, such as CT. Expected CT utilization was 100%, but actual utilization was 78% (Table 2) . Overall, mean DBS cost for both awake and asleep approaches was $39,152 ± $5340. Mean LOS was 1.18 days and readmission rate was 4.3%. The mean OR time was 285.85 ± 57.83 minutes. There were no deaths (Table 3) .
awake versus asleep dbs
There were no significant differences in readmissions, LOS, intensive care unit (ICU) LOS, OR time, and cost. Costs included ICD-9 inpatient procedure code 0293 and outpatient costs closely associated with DBS, such as implantation of an IPG ( Table 3 ). The mean cost of asleep DBS ($38,850 ± $4830) was lower than that of awake DBS ($40,052 ± $6604), which was not significant. However, there was a significant difference in the standard deviation (p = 0.0034).
benchmarking dbs: icd-9 procedure code 0293
OHSU's observed cost for implanting a neurostimulator lead was less than the expected cost (ratio 0.97; Fig. 1 ). In 2013, the average cost of implanting neurostimulator leads at OHSU was $17,150, less than the group median of $34,052 (Table 4 ). OHSU's cost for these procedures also appeared to be lower than the median among institutions that performed at least 5 of these procedures a year (Fig.  2, Table 4 ).
Total DBS costs over time were compared, as indicated in Fig. 3 by the awake DBS mean (Fig. 3 , grey line) and asleep DBS mean (Fig. 3, black line) . One observation (1.85%) is above the upper control limit in the awake period. Three observations (1.88%) exceed 3 times the standard deviation in the asleep period. The mean cost during the period of asleep DBS procedures was lower than that during the period of awake DBS procedures, but was not statistically significant. After adjusting for severity, varia- tion in cost was lower for asleep DBS when compared with awake DBS, and this difference was statistically significant (Table 3) .
Costs by revenue category and DBS procedure were compared in Table 5 . The column in the table labeled "Total Cost (%)" indicates the percentage of total cost that is accounted for by the revenue category. After adjusting for severity of illness, the revenue categories indicated a significant difference in average costs by DBS procedure. For example, the per-patient costs of medical or surgical supplies were $26,515 ± $2914 and $23,172 ± $3266 for awake and asleep DBS procedures, respectively. Medical or surgical supplies account for 61.3% of the total cost of DBS procedures. Other revenue categories that were significantly lower for asleep DBS included anesthesia and MRI. Costs of OR services, recovery room, and CT increased with asleep DBS.
Total OR time for implantation of neurostimulator leads was calculated and upper and lower control limits were determined by data from the period prior to January 5, 2011, when awake DBS was performed at OHSU (Fig.  4) . The mean OR times of awake DBS versus asleep DBS were compared, as indicated in Fig. 4 by the mean awake (Fig. 4 , grey line) and mean asleep (Fig. 4, black line) . One observation (1.8%) is above the upper control limit in the awake period. Four observations (2.5%) exceed 3 times the standard deviation in the asleep period. The mean OR time during the asleep period appears to be higher than that during the awake period (Table 3) . However, in a severityadjusted model, this difference was not statistically significant. The difference in variance of OR time by awake versus asleep DBS, after adjusting for severity, remained not significant.
discussion
There is a growing interest in the use of image guidance 18, 21 as an alternative to microelectrode mapping 15 for DBS electrode implantation. We have presented a detailed analysis of the costs of DBS implantation performed under general anesthesia with image guidance at OHSU. We have compared this result to a historical group of patients at OHSU who underwent DBS implantation under local anesthesia with microelectrode guidance. Costs included ICD-9 inpatient procedure code 0293 and outpatient costs closely associated with DBS, such as implantation of an IPG. The results show that there were no differences in readmissions, LOS, ICU LOS, OR time, and cost when these two types of procedures were compared within the same institution.
A more comprehensive understanding of costs associated with DBS requires outpatient and inpatient data. However, for the purposes of this study, obtaining outpatient data from other UHC institutions was not feasible. Despite this limitation, OHSU's cost for these procedures was lower than the median among comparable UHC institutions. We suggest that a comprehensive assessment of costs at high-volume UHC hospitals for these procedures would be interesting and add a higher level of confidence to future cost-effectiveness analyses. We are confident that cost analysis for DBS will become increasingly important as health care expenditures come under increasing pressure, and as these procedures are more in demand in an aging population.
This study may have limited generalizability, as it shows the experience of a single center; however, the performing surgeon at the center has set the standard for asleep DBS procedure methodology. Furthermore, the effects we show are the effects of the single surgeon performing first awake DBS, then asleep DBS. The differences we see in cost variation may be due to either secular trends or the change in practice from awake to asleep DBS. While we adjust for patient characteristics, it is possible that unmeasured factors may be causing the decrease in cost variation. Another potential bias for this study may include unobserved changes in practice style that could have occurred during the study period; however, this limitation may have been mitigated by the fact that the procedures were performed by the same physician. Practice patterns beyond the change from the awake to the asleep method are unlikely to have varied significantly.
One outcome of this study is that using the asleep DBS strategy, OR time and the cost variation of the procedure appear to be decreasing over time, presumably as the procedure becomes more routine and predictable from the standpoint of imaging and intraoperative workflow. Of course, outcome is the most important aspect of any surgical innovation. The outcome in this particular analysis was cost. We are compiling our clinical outcome statistics, with long-term follow-up, in a subsequent report.
conclusions
In this single academic medical center cost analysis, DBS performed while the patient was asleep was associated with a lower cost variation relative to the awake procedure. Furthermore, costs for asleep DBS compared favorably to those of high-volume UHC-affiliated institutions. 
